{"id":14387,"date":"2025-09-22T11:21:57","date_gmt":"2025-09-22T05:51:57","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=14387"},"modified":"2025-09-22T17:20:01","modified_gmt":"2025-09-22T11:50:01","slug":"aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Aptus Pharma IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]India\u2019s IPO market continues to attract niche companies in 2025, providing investors with opportunities to invest in high-growth sectors. Among these, Aptus Pharma Ltd, a pharmaceutical marketing and distribution company, is set to open its IPO on September 23, 2025, offering investors exposure to a robust distribution network, diverse therapeutic segments, and strategic manufacturing alliances.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_Aptus_Pharma_Ltd\"><\/span><strong>About Aptus Pharma Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Incorporated in 2010, Aptus Pharma Ltd. operates in the marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes a broad range of formulations across multiple therapeutic areas, including:<\/p>\n<ul>\n<li><strong>Aptus Pharma:<\/strong> Acute therapies such as anti-infectives, pain management<\/li>\n<li><strong>Aptus CD Care:<\/strong> Chronic therapies<\/li>\n<li><strong>Aptus Wellcare:<\/strong> Wellness and nutraceutical products<\/li>\n<li><strong>Aptus Global:<\/strong> Exports to overseas markets<\/li>\n<\/ul>\n<p>As of March 31, 2025, the company had 194 pharmaceutical formulations spanning eleven therapeutic segments. Its warehouse spans 15,732 sq. ft. and 1,989 sq. ft. in Ahmedabad, Gujarat. Distribution is supported by 125 direct and sub-distributors and a sales team of 54 field personnel. The company has 70 employees on payroll.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Strengths\"><\/span><strong>Competitive Strengths:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Diversified product portfolio<\/li>\n<li>Robust distribution network<\/li>\n<li>Strategic manufacturing alliances across Gujarat, Uttarakhand, and Himachal Pradesh<\/li>\n<li>Competitive and cost-effective pricing<\/li>\n<li>Experienced management team<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Aptus_Pharma_IPO_Details\"><\/span><strong>Aptus Pharma IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <a href=\"https:\/\/www.torusdigital.com\/ipo\/aptus-pharma-ltd-ipo\">Aptus Pharma IPO<\/a> is a book-building issue of \u20b913.02 crore, entirely a fresh issue of 0.19 crore shares. The IPO will list on the BSE SME.<\/p>\n<p><a href=\"https:\/\/torusdigital.go.link\/hgQeE\" target=\"_blank\" rel=\"noopener\"><br \/>\n<img decoding=\"async\" class=\"responsive-img\" src=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/07\/Desktop-1.jpg\" alt=\"\" \/><br \/>\n<\/a><\/p>\n<style>\n  .responsive-img {<br \/>    display: block;<br \/>    margin-left: auto;<br \/>    margin-right: auto;<br \/>    width: 100%;<br \/>    max-width: 900px;<br \/><\/style>\n<h3><span class=\"ez-toc-section\" id=\"IPO_Timeline\"><\/span><strong>IPO Timeline:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Event<\/strong><\/td>\n<td><strong>Date (Tentative)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>IPO Open Date<\/td>\n<td>Sep 23, 2025<\/td>\n<\/tr>\n<tr>\n<td>IPO Close Date<\/td>\n<td>Sep 25, 2025<\/td>\n<\/tr>\n<tr>\n<td>Tentative Allotment<\/td>\n<td>Sep 26, 2025<\/td>\n<\/tr>\n<tr>\n<td>Initiation of Refunds<\/td>\n<td>Sep 29, 2025<\/td>\n<\/tr>\n<tr>\n<td>Credit of Shares to Demat<\/td>\n<td>Sep 29, 2025<\/td>\n<\/tr>\n<tr>\n<td>Tentative Listing Date<\/td>\n<td>Sep 30, 2025<\/td>\n<\/tr>\n<tr>\n<td>Cut-off time for UPI mandate confirmation<\/td>\n<td>5 PM on Sep 25, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_IPO_Details\"><\/span><strong>Key IPO Details:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><strong>Parameter<\/strong><\/td>\n<td><strong>Details<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Face Value<\/td>\n<td>\u20b910 per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Price Band<\/td>\n<td>\u20b965 \u2013 \u20b970 per share<\/td>\n<\/tr>\n<tr>\n<td>Lot Size<\/td>\n<td>2,000 shares<\/td>\n<\/tr>\n<tr>\n<td>Total Issue Size<\/td>\n<td>18.6 lakh shares (\u20b913.02 Cr)<\/td>\n<\/tr>\n<tr>\n<td>Sale Type<\/td>\n<td>Fresh Capital<\/td>\n<\/tr>\n<tr>\n<td>Reserved for Market Maker<\/td>\n<td>94,000 shares (\u20b90.658 Cr)<\/td>\n<\/tr>\n<tr>\n<td>Issue Type<\/td>\n<td>Bookbuilding IPO<\/td>\n<\/tr>\n<tr>\n<td>Listing At<\/td>\n<td>BSE SME<\/td>\n<\/tr>\n<tr>\n<td>Shareholding Pre-Issue<\/td>\n<td>50,00,000 shares<\/td>\n<\/tr>\n<tr>\n<td>Shareholding Post-Issue<\/td>\n<td>68,60,000 shares<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Investor_Category_Reservation\"><\/span><strong>Investor Category Reservation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Investor Category<\/strong><\/td>\n<td><strong>Shares Offered<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Maker<\/td>\n<td>94,000 (5.05%)<\/td>\n<\/tr>\n<tr>\n<td>QIB<\/td>\n<td>8,80,000 (47.31%)<\/td>\n<\/tr>\n<tr>\n<td>NII (HNI)<\/td>\n<td>2,66,000 (14.30%)<\/td>\n<\/tr>\n<tr>\n<td>Retail<\/td>\n<td>6,20,000 (33.33%)<\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>18,60,000 (100%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Anchor_Investors\"><\/span><strong>Anchor Investors:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Bid Date<\/strong><\/td>\n<td><strong>Shares Offered<\/strong><\/td>\n<td><strong>Portion Size (\u20b9 Cr)<\/strong><\/td>\n<td><strong>50% Lock-in<\/strong><\/td>\n<td><strong>90% Lock-in<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sep 22, 2025<\/td>\n<td>5,28,000<\/td>\n<td>3.70<\/td>\n<td>Oct 26, 2025<\/td>\n<td>Dec 25, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Lot_Size_Investment\"><\/span><strong>Lot Size &amp; Investment:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Application<\/strong><\/td>\n<td><strong>Lots<\/strong><\/td>\n<td><strong>Shares<\/strong><\/td>\n<td><strong>Amount<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Retail (Min)<\/td>\n<td>2<\/td>\n<td>4,000<\/td>\n<td>\u20b92,80,000<\/td>\n<\/tr>\n<tr>\n<td>Retail (Max)<\/td>\n<td>2<\/td>\n<td>4,000<\/td>\n<td>\u20b92,80,000<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Min)<\/td>\n<td>3<\/td>\n<td>6,000<\/td>\n<td>\u20b94,20,000<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Max)<\/td>\n<td>7<\/td>\n<td>14,000<\/td>\n<td>\u20b99,80,000<\/td>\n<\/tr>\n<tr>\n<td>B-HNI (Min)<\/td>\n<td>8<\/td>\n<td>16,000<\/td>\n<td>\u20b911,20,000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Also Read:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/jaro-institute-ipo-opens-key-details-investors-shouldnt-miss\/\">Jaro Institute IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/seshaasai-technologies-ipo-opens-key-details-investors-shouldnt-miss\/\">Seshaasai Technologies IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/true-colors-ipo-opens-key-details-investors-shouldnt-miss\/\">True Colors IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/solarworld-energy-solutions-ipo-opens-key-details-investors-shouldnt-miss\/\">Solarworld Energy Solutions IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/anand-rathi-share-ipo-opens-key-details-investors-shouldnt-miss\/\">Anand Rathi Share IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/nsb-bpo-solutions-ipo-opens-key-details-investors-shouldnt-miss\/\">NSB BPO Solutions IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Promoter_Holding\"><\/span><strong>Promoter Holding:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The promoters include Tejash Maheshchandra Hathi, Chatrabhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya, Milly Chetan Lalseta, Riddhish Natwarlal Tanna, Gaurang Rameshchandra Thakker, Kripaliben Mayank Thakker, and Kunjal Piyushbhai Unadkat.<\/p>\n<ul>\n<li><strong>Pre-IPO:<\/strong> 100%<\/li>\n<li><strong>Post-IPO:<\/strong> 72.89%<\/li>\n<\/ul>\n<p><strong>Book Running Lead Manager:<\/strong> <a href=\"https:\/\/www.torusdigital.com\/stocks\/interactive-financial-services-ltd-share-price\">Interactive Financial Services Ltd.<\/a><br \/>\n<strong>Registrar:<\/strong> Bigshare Services Pvt. Ltd.<br \/>\n<strong>Market Maker:<\/strong> Market-Hub Stock Broking Pvt. Ltd.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptus_Pharma_Ltd_Financials\"><\/span><strong>Aptus Pharma Ltd.: Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Financial_Highlights_%E2%82%B9_Crore\"><\/span><strong>Financial Highlights (\u20b9 Crore):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Period Ended<\/strong><\/td>\n<td><strong>31 Mar 2025<\/strong><\/td>\n<td><strong>31 Mar 2024<\/strong><\/td>\n<td><strong>31 Mar 2023<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Assets<\/td>\n<td>21.92<\/td>\n<td>10.03<\/td>\n<td>6.22<\/td>\n<\/tr>\n<tr>\n<td>Total Income<\/td>\n<td>24.64<\/td>\n<td>17.88<\/td>\n<td>13.90<\/td>\n<\/tr>\n<tr>\n<td>Profit After Tax<\/td>\n<td>3.10<\/td>\n<td>0.80<\/td>\n<td>0.19<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>4.76<\/td>\n<td>1.49<\/td>\n<td>0.57<\/td>\n<\/tr>\n<tr>\n<td>Net Worth<\/td>\n<td>6.97<\/td>\n<td>1.77<\/td>\n<td>0.97<\/td>\n<\/tr>\n<tr>\n<td>Reserves &amp; Surplus<\/td>\n<td>1.97<\/td>\n<td>1.47<\/td>\n<td>0.67<\/td>\n<\/tr>\n<tr>\n<td>Total Borrowing<\/td>\n<td>10.36<\/td>\n<td>5.31<\/td>\n<td>2.21<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_Performance_Indicators_FY2025\"><\/span><strong>Key Performance Indicators (FY2025):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>Market Cap:<\/strong> \u20b948.02 Cr<\/li>\n<li><strong>ROE: <\/strong>44.50%<\/li>\n<li><strong>ROCE: <\/strong>45.66%<\/li>\n<li><strong>Debt\/Equity: <\/strong>1.49<\/li>\n<li><strong>RoNW: <\/strong>44.50%<\/li>\n<li><strong>EBITDA Margin: <\/strong>19.31%<\/li>\n<li><strong>EPS Pre-IPO:<\/strong> \u20b96.20 | <strong>Post-IPO:<\/strong> \u20b94.52<\/li>\n<li><strong>P\/E Pre-IPO: <\/strong>11.29x | <strong>Post-IPO:<\/strong> 15.49x<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Objects_of_the_Issue\"><\/span><strong>Objects of the Issue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>S.No<\/strong><\/td>\n<td><strong>Object<\/strong><\/td>\n<td><strong>Expected Amount (\u20b9 Cr)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Capital Expenditure for Office Premises with furniture and Industrial Racks<\/td>\n<td>1.63<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Working Capital<\/td>\n<td>8.00<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>General Corporate Purposes<\/td>\n<td>Balance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Industry_Outlook\"><\/span><strong>Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <a href=\"https:\/\/www.torusdigital.com\/stocks\/sectors\/pharmaceuticals\">Indian pharmaceutical market<\/a> continues to expand, driven by:<\/p>\n<ul>\n<li>Rising domestic healthcare demand<\/li>\n<li>Increasing awareness and chronic disease prevalence<\/li>\n<li>Expanding distribution channels across semi-urban and rural regions<\/li>\n<li>Growing export opportunities for generic formulations<\/li>\n<\/ul>\n<p>Aptus Pharma\u2019s diversified therapeutic portfolio, strong distribution network, and strategic manufacturing alliances position it well to capture growth in domestic and international pharmaceutical markets.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptus_Pharma_IPO_Peer_Comparison\"><\/span><strong>Aptus Pharma IPO: Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors looking at Aptus Pharma may also consider its industry peers to understand relative performance and market positioning. Key peers include <a href=\"https:\/\/www.torusdigital.com\/stocks\/zota-health-care-ltd-share-price\">Zota Health Care Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/sunrest-lifescience-ltd-share-price\">Sunrest Lifescience Ltd<\/a>, and <a href=\"https:\/\/www.torusdigital.com\/stocks\/lincoln-pharmaceuticals-ltd-share-price\">Lincoln Pharmaceuticals Ltd<\/a>. Comparing financial metrics such as revenue growth, profitability, and valuation multiples across these companies can provide valuable insights for making informed investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aptus Pharma Ltd. offers investors a promising opportunity in the pharmaceutical distribution and manufacturing sector. With consistent revenue and profit growth, a diversified portfolio, and strategic distribution and manufacturing capabilities, the company is well-positioned for expansion. However, investors should consider risks such as regulatory changes, competition in the pharmaceutical sector, and dependency on key distributors.<\/p>\n<p>If you are exploring more investment opportunities, check out our dedicated page on <a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO listings<\/a> to stay updated on the latest market offerings.<\/p>\n<p><span data-contrast=\"auto\">\u202f\u202f\u202f\u202f\u202f<\/span>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--14387 \"  data-post-id=\"14387\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results rmp-rating-widget__results--hidden\">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">0<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">0<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated \">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p><\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Faptus-pharma-ipo-opens-key-details-investors-shouldnt-miss%2F&t=Aptus+Pharma+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Aptus+Pharma+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Faptus-pharma-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Aptus+Pharma+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Faptus-pharma-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Faptus-pharma-ipo-opens-key-details-investors-shouldnt-miss%2F&title=Aptus+Pharma+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]India\u2019s IPO market continues to attract niche companies in 2025, providing investors with opportunities to invest in high-growth sectors. Among these, Aptus Pharma Ltd, a pharmaceutical marketing and distribution company, is set to open its IPO on September 23, 2025, offering investors exposure to a robust distribution network, diverse therapeutic segments,","protected":false},"author":1,"featured_media":14024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-14387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aptus Pharma IPO Opens: Key Details Investors Must Know<\/title>\n<meta name=\"description\" content=\"Aptus Pharma IPO presents an opportunity for investors to participate in a leading pharmaceutical distributor and manufacturer with a diversified product portfolio and strong growth.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptus Pharma IPO Opens: Key Details Investors Must Know\" \/>\n<meta property=\"og:description\" content=\"Aptus Pharma IPO presents an opportunity for investors to participate in a leading pharmaceutical distributor and manufacturer with a diversified product portfolio and strong growth.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T05:51:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T11:50:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptus Pharma IPO Opens: Key Details Investors Must Know","description":"Aptus Pharma IPO presents an opportunity for investors to participate in a leading pharmaceutical distributor and manufacturer with a diversified product portfolio and strong growth.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/","og_locale":"en_US","og_type":"article","og_title":"Aptus Pharma IPO Opens: Key Details Investors Must Know","og_description":"Aptus Pharma IPO presents an opportunity for investors to participate in a leading pharmaceutical distributor and manufacturer with a diversified product portfolio and strong growth.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/","og_site_name":"Blog","article_published_time":"2025-09-22T05:51:57+00:00","article_modified_time":"2025-09-22T11:50:01+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/","name":"Aptus Pharma IPO Opens: Key Details Investors Must Know","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","datePublished":"2025-09-22T05:51:57+00:00","dateModified":"2025-09-22T11:50:01+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Aptus Pharma IPO presents an opportunity for investors to participate in a leading pharmaceutical distributor and manufacturer with a diversified product portfolio and strong growth.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/aptus-pharma-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Aptus Pharma IPO Opens: Key Details Investors Shouldn\u2019t Miss"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/14387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=14387"}],"version-history":[{"count":2,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/14387\/revisions"}],"predecessor-version":[{"id":14400,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/14387\/revisions\/14400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14024"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=14387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=14387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=14387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}